These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 29370292)

  • 21. Correction: Cordycepin promotes apoptosis in renal carcinoma cells by activating the MKK7-JNK signaling pathway through inhibition of c-FLIPL expression.
    PLOS ONE Staff
    PLoS One; 2018; 13(1):e0191535. PubMed ID: 29338051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion.
    Clark SS; Zhong L; Filiault D; Perman S; Ren Z; Gould M; Yang X
    Clin Cancer Res; 2003 Oct; 9(12):4494-504. PubMed ID: 14555523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
    Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
    Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correction: The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers.
    PLOS ONE Staff
    PLoS One; 2019; 14(2):e0212697. PubMed ID: 30768650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.
    Zhao C; Xiao H; Wu X; Li C; Liang G; Yang S; Lin J
    Oncotarget; 2015 Jun; 6(16):14472-87. PubMed ID: 25961376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
    Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of Ras/MEK/ERK signaling in chronic subdural hematoma outer membranes.
    Osuka K; Watanabe Y; Usuda N; Atsuzawa K; Aoyama M; Niwa A; Nakura T; Takayasu M
    Brain Res; 2012 Dec; 1489():98-103. PubMed ID: 23063714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
    Chang F; Steelman LS; Lee JT; Shelton JG; Navolanic PM; Blalock WL; Franklin RA; McCubrey JA
    Leukemia; 2003 Jul; 17(7):1263-93. PubMed ID: 12835716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MEK/ERK signaling pathway in apoptosis of SW620 cell line and inhibition effect of resveratrol.
    Chen H; Jin ZL; Xu H
    Asian Pac J Trop Med; 2016 Jan; 9(1):49-53. PubMed ID: 26851786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
    Bahr JC; Robey RW; Luchenko V; Basseville A; Chakraborty AR; Kozlowski H; Pauly GT; Patel P; Schneider JP; Gottesman MM; Bates SE
    Oncotarget; 2016 Oct; 7(43):69804-69815. PubMed ID: 27634878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correction: Tissue factor pathway inhibitor for prediction of placenta-mediated adverse pregnancy outcomes in high-risk women: AngioPred study.
    Di Bartolomeo A; Chauleur C; Tardy B; Piot M; Gris JC; Chapelle C; Noblot E; Laporte S; Raia-Barjat T
    PLoS One; 2017; 12(7):e0181474. PubMed ID: 28704568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correction: Correction: Direct and Indirect Effects of Five Factor Personality and Gender on Depressive Symptoms Mediated by Perceived Stress.
    PLOS ONE Staff
    PLoS One; 2018; 13(1):e0191142. PubMed ID: 29304170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
    Costa-Cabral S; Brough R; Konde A; Aarts M; Campbell J; Marinari E; Riffell J; Bardelli A; Torrance C; Lord CJ; Ashworth A
    PLoS One; 2017; 12(4):e0176578. PubMed ID: 28426773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
    Kiessling MK; Curioni-Fontecedro A; Samaras P; Lang S; Scharl M; Aguzzi A; Oldridge DA; Maris JM; Rogler G
    PLoS One; 2017; 12(1):e0170851. PubMed ID: 28107499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correction: PID1 alters the antilipolytic action of insulin and increases lipolysis via inhibition of AKT/PKA pathway activation.
    Yin C; Liu WH; Liu Y; Wang L; Xiao Y
    PLoS One; 2019; 14(6):e0218721. PubMed ID: 31206557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction: Survivin Mutant Protects Differentiated Dopaminergic SK-N-SH Cells Against Oxidative Stress.
    Baratchi S; Kanwar RK; Kanwar JR
    PLoS One; 2018; 13(3):e0194587. PubMed ID: 29543866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.